ABSTRACT
Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for more than 80% of primary lung cancer. Platinum-based chemotherapy is the traditional standard for the treatment of advanced NSCLC, but the 5-years survival rate is still very low, less than 5%. Angiogenesis plays an important role in the growth, proliferation and metastasis of solid tumors. Angiogenesis inhibitors affect the tumor microenvironment, degenerate existing tumor blood vessels and inhibit tumor angiogenesis. Angiogenesis inhibitors are now one of the indispensable treatments for patients with advanced NSCLC through continuous development of new angiogenesis inhibitor and improvement of drug accessibility. This consensus is based on the "Expert consensus on anti-angiogenic drug therapy for advanced non-small cell lung cancer in China (2019 Edition)" , combines with clinical research evidence published in the past years and clinical experience. The consensus-writing group compiles a consensus of guiding clinical departments related to lung cancer treatment to use anti-angiogenic drugs in a standardized manner, and further improves the level of standardized diagnosis and treatment of lung cancer.
Subject(s)
Humans , Angiogenesis Inhibitors/therapeutic use , Carcinoma, Non-Small-Cell Lung/pathology , China , Consensus , Lung Neoplasms/pathology , Neoplasm StagingABSTRACT
Lung cancer is the most frequently diagnosed cancer and the most common cause of cancer mortality in China. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers. The mutation rate of epidermal growth factor receptor (EGFR) gene is relatively high, accounts for 32%~38% of all NSCLC. During the last decade, the application of EGFR specific tyrosine kinase inhibitors (TKI) significantly improved prognosis of NSCLC patients with sensitive EGFR mutations. Thus, the research and development of third generation EGFR-TKI have entered the period of rapid development. The fourth generation EGFR-TKI which targeting EGFR C797S has even begun clinical development in China. This review will discuss the clinical research and drug review of EGFR-TKI from the perspective of drug review.
ABSTRACT
Objective@#The aim of this retrospective study was to evaluate the prognostic significance of pretreatment Neutrophil-to-Lymphocyte Ratio(NLR) in locally advanced non-small cell lung cancer(NSCLC) patients treated with thoracic radiotherapy.@*Methods@#We retrospectively analyze 420 patients who received thoracic radiotherapy alone, sequential chemoraiotherapy or concurrent chemoradiotherapy for locally advanced stage NSCLC from January 2007 to December 2010 of our hospital. The patients were divided into two groups (high NLR group and low NLR group) with appropriate cutoff point using the receiver operating characteristic (ROC) curve method. The survival curve was established by Kaplan-Meier method. The Log-rank test was used to compare the survival of the two NLR groups and the multivariate analysis was carried out by Cox regression model.@*Results@#Among the 420 patients, 99 received radiotherapy alone, 139 received sequential chemoradiotherapy and 182 received concurrent chemoradiotherapy. 345 patients died and 75 were still alive. The median follow-up time was 5.2 years and the median overall survival was 22 months. The cut-off value of pretreatment NLR was 2.1. The 5-year PFS and OS rates in high NLR group and low NLR group were 10.6% vs 15.7% (P=0.033) and 15.5% vs 22.7% (P=0.012). Multivariate analysis confirmed that pretreatment NLR (hazard ratio 1.06, P=0.041) was independent prognostic factor of OS.@*Conclusions@#Our study revealed that the pretreatment NLR is the independent prognostic factor of OS in patients with locally advanced stage NSCLC treated with thoracic radiotherapy. However, NLR is still greatly influenced by patient′s condition and treatment which needs further research.
ABSTRACT
With the development of the main tumor gene sequencing projects,driver mutations have been put into the highlight due to its significant meaning on the cancer occurrence,development as well as treatment.In the past decade,based on the finding of new driver mutations,the knowledge of non-small cell lung cancer (NSCLC) have been improved from the traditional pathological classification to the current molecular classification.Meanwhile,NSCLC patients are no longer looked as an assembly of the same type tumor but various individuals with different molecular biology behavior with the different sensitivity to the targeted drugs.This article focuses on the recent discovery advances of driver mutations in lung adenocarcinoma.
ABSTRACT
Objective To analyze the factors affecting the efficacy of postoperative radiotherapy (PORT) in node-positive non-small cell lung cancer (NSCLC). Methods 480 patients with stage N_1-N_2 NSCLC after radical surgery were retrospectively reviewed. Of them, 267 patients received adjuvant chemotherapy and 121 received PORT. All patients were grouped based on the N stage, tumor size and lymph node positive ratio (the percentage of positive lymph nodes from the detected lymph nodes, LNPR). Group 1 included patients with tumor size ≤3 cm and LNPR ≤33%, group 2 was tumor size > 3 cm or LNPR > 33%, and group 3 was tumor size > 3 cm and LNPR > 33%. The endpoints were the local recurrence free survival (LRFS) and overall survival (OS). Kaplan-Meier method and Cox's proportional hazards regression model were used for the statistic analyses. Results PORT improved the overall survival only in patients with N_2 disease. Both tumor size and LNPR significantly influenced the efficacy of PORT. The 5-year LRFS for patients with vs. without PORT in the group 1, 2 and 3 were 55% vs. 60% (χ~2 = 0.03,P-0.869), 42% vs. 50% (χ~2 =0.31,P=0.547),and 62% vs. 52% (χ~2=4.25,P=0.036), respectively;and the corresponding OS were 22% vs. 50% (χ~2 = 1.65 ,P =0. 199), 26% vs. 22% (χ~2= 0. 13,P=0.786) and 42% vs. 16% (χ~2= 15.33,P=0.000), respectively. Conclusions Tumor size and LNPR significantly impact the efficacy of PORT . For patients with stage N_2 NSCLC , PORT could improve local recurrence free survival and overall survival when tumor size > 3 cm and LNPR >33%.